부산대학교 도서관

Novel 1,3,4-oxadiazole-functionalized pyrido[2,3-d]pyrimidine derivatives were prepared starting from 2-amino-6-(thiophen-2-yl)-4-(trifluoromethyl)nicotinonitrile, which was reacted with trifluoroacetic acid in the presence of conc. H2SO4 and further with bromoethyl acetate to obtain ethyl 2-{4-oxo-7-(thiophen-2-yl)-2,5-bis(trifluoromethyl)pyrido[2,3-d]pyrimidin-3(4H)-yl}acetate. The reaction of the latter products with hydrazine hydrate gave 2-{4-oxo-7-(thiophen-2-yl)-2,5-bis(trifluoromethyl)pyrido[2,3-d]pyrimidin-3(4H)-yl}acetohydrazide. The subsequent treatment of the products with a series of aromatic acids resulted in the synthesis of 3-[(5-aryl-1,3,4-oxadiazol-2-yl)methyl]-7-(thiophen-2-yl)-2,5-bis(trifluoromethyl)pyrido[2,3-d]pyrimidin-4(3H)-ones and 2-aryl-5-({[7-(thiophen-2-yl)-2,5-bis(trifluoromethyl)pyrido[2,3-d]pyrimidin-4-yl]oxy}methyl)-1,3,4-oxadiazoles. All the synthesized final products were tested for anticancer activity against 4 human cancer cell lines: such as A549-Lung cancer (CCL-185), MCF7-Breast cancer (HTB-22), DU145-Prostate cancer (HTB-81), and HeLa-Cervical cancer (CCL-2). Some of the tested compounds showed promising anticancer activity. [ABSTRACT FROM AUTHOR]